A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors

Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting classes of targeted therapy agents for cancers with homologous recombination (HR) deficiency. However, many patients without apparent HR defects also respond well to PARP inhibitors/cisplatin. The biomarker responsible for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chao, Guo, Qiang, Chen, Lifeng, Wu, Zheming, Yan, Xiao-Jian, Zou, Chengyang, Zhang, Qiuxue, Tan, Jiahong, Fang, Tian, Rao, Qunxian, Li, Yang, Shen, Shizhen, Deng, Min, Wang, Liewei, Gao, Huanyao, Yu, Jia, Li, Hu, Zhang, Cheng, Nowsheen, Somaira, Kloeber, Jake, Zhao, Fei, Yin, Ping, Teng, Chunbo, Lin, Zhongqiu, Song, Kun, Yao, Shuzhong, Yao, Liangqing, Wu, Lingying, Zhang, Yong, Cheng, Xiaodong, Gao, Qinglei, Yuan, Jian, Lou, Zhenkun, Zhang, Jin-San
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170152/
https://www.ncbi.nlm.nih.gov/pubmed/37160887
http://dx.doi.org/10.1038/s41392-023-01401-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170152/
https://www.ncbi.nlm.nih.gov/pubmed/37160887
http://dx.doi.org/10.1038/s41392-023-01401-y

Ejemplares similares